Brief: Laurus Labs Concludes USFDA Audit For API Manufacturing Facility At Hyderabad
13/09/2024 14:02
Sept 13 (Reuters) - Laurus Labs Ltd LAUL.NS :
* CONCLUDES USFDA AUDIT FOR API MANUFACTURING FACILITY AT
HYDERABAD
* USFDA AUDIT COMPLETED WITHOUT ANY 483 OBSERVATION.
Source text for Eikon: ID:nBSEbR9x4Z
Further company coverage: LAUL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Laurus Labs
See all newsIndia's Laurus Labs hits record high as Q2 profit more than doubles
Brief: Laurus Labs Declares Dividend Of 1 Rupee Per Share
Brief: Laurus Labs Invests 1.08 Billion Rupees Into KRKA Pharma Via Rights Issue
Brief: Laurus Labs Invests 120.96 Million Rupees In Kurnool Renewables Via Rights Issue
Four Indian stocks to be added, three removed from key global index in MSCI's August rejig